Barrington raised the firm’s price target on Haemonetics (HAE) to $90 from $86 and keeps an Outperform rating on the shares after a Q2 beat and FY26 guidance raise.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE: